Harmony Biosciences Holdings, Inc. (HRMY) Form 8-K — Aug 4, 2026
Harmony Biosciences reported Q2 2026 net product revenue of $261.3 million, a 30% year-over-year increase driven by continued strong demand for WAKIX. Net income rose to $75.4 million, or $1.28 per diluted share, while the company highlighted favorable Phase 1 single ascending dose data for its orexin-2 agonist BP-205, supporting a potential best-in-class profile.
Key figures
- Eps
- 1.28
- Revenue
- 261.3
- Guidance
- $1.0B to $1.04B
- Net Income
- 75.4
- Revenue Yoy
- 30%
- Cash Position
- 962.5
Price after filing
1 day: -0.7%7 days: +10.2%30 days: +19.5%
Close on the filing date to close N calendar days later (from $35.86). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.